Potential effects of peroxisome proliferator-activated receptor activator on LPS-induced lung injury in rats

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 4, 2009, Pages 318-325

  Wang, Xiangdong ^a   Wang, Yaoli ^a   Zhao, Xia ^b   Andersson, Roland ^b   Song, Zhenju ^a   Yang, Dong ^a   Bai, Chunxue ^a  

^a FUDAN UNIVERSITY   (China)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

COPD; Emphysema; Hyperinflation; LPS; PPAR ; TIMP 1; VEGF

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HYPERINFLATION; LEUKOCYTE; LUNG ALVEOLUS; LUNG INJURY; LUNG LAVAGE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; INTERFERON-GAMMA; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; LUNG; LUNG DISEASES; LUNG VOLUME MEASUREMENTS; PNEUMONIA; PPAR GAMMA; PROSTAGLANDIN D2; PULMONARY ALVEOLI; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RATS; RATS, WISTAR; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 67349288556     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.01.004     Document Type: Article

References (34)

1. Devereux G. ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors. BMJ 332 (2006) 1142-1144
2. Gelb A.F., Taylor C.F., McClean P.A., Shinar C.M., Rodrigues M.T., Gutierrez C.A., et al. Tiotropium and simplified detection of dynamic hyperinflation. Chest 131 (2007) 690-695
3. Alm A.S., Ingvarsson A., and Wang X.D. Significance of lung hyperinflation in chronic obstructive pulmonary disease. J Organ Dysfunction 3 (2007) 44-54
4. Yoshida T., and Tuder R.M. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 87 (2007) 1047-1082
5. Libby P., and Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 99 (2007) 27B-40B
6. Standiford T.J., Keshamouni V.G., and Reddy R.C. Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc Am Thorac Soc 2 (2005) 226-231
7. Kawahito Y., Kondo M., Tsubouchi Y., Hashiramoto A., Bishop-Bailey D., Inoue K., et al. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 106 (2000) 189-197
8. Jansson A.H., Smailagic A., Andersson A.M., Zackrisson C., Fehniger T.E., Stevens T.R., et al. Evaluation of excised lung gas volume measurements in animals with genetic or induced emphysema. Respir Physiol Neurobiol 150 (2006) 240-250
9. Larsson L., Szponar B., and Pehrson C. Tobacco smoking increases dramatically air concentrations of endotoxin. Indoor Air 14 (2004) 421-424
10. Vernooy J.H., Dentener M.A., van Suylen R.J., Buurman W.A., and Wouters E.F. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 26 (2002) 152-159
11. Savov J.D., Gavett S.H., Brass D.M., Costa D.L., and Schwartz D.A. Neutrophils play a critical role in development of LPS-induced airway disease. Am J Physiol Lung Cell Mol Physiol 283 (2002) L952-L962
12. Kharitonov S.A., and Sjobring U. Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. Contrib Microbiol 14 (2007) 83-100
13. Jansson A.H., Smailagic A., Andersson A.M.D., Zackrisson C., Fehniger T.E., Stevens T.S., et al. Evaluation of excised lung gas volume measurements in animals with genetic or induced emphysema. Respir Physiol Neurobiol 150 (2006) 240-250
14. Martorana P.A., and Lungarella G. Genetic deficiency in alpha 1 proteinase inhibitor (α1 PI) associated with emphysema. Lab Anim Sci 48 (1998) 460-462
15. Lee K.M., Renne R.A., Harbo S.J., Clark M.L., Johnson R.E., and Gideon K.M. 3-week inhalation exposure to cigarette smoke and/or lipopolysaccharide in AKR/J mice. Inhal Toxicol 19 (2007) 23-35
16. Sandstrom T., Bjermer L., and Rylander R. Lipopolysaccharide (LPS) inhalation in healthy subjects increases neutrophils, lymphocytes and fibronectin levels in bronchoalveolar lavage fluid. Eur Respir J 5 (1992) 992-996
17. Tanaseanu C., Tudor S., Tamsulea I., Marta D., Manea G., and Moldoveanu E. Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus. Eur J Med Res 12 (2007) 145-151
18. Krenn K., Klepetko W., Taghavi S., Paulus P., and Aharinejad S. Vascular endothelial growth factor increases pulmonary vascular permeability in cystic fibrosis patients undergoing lung transplantation. Eur J Cardiothorac Surg 32 (2007) 35-41
19. Kanazawa H., Asai K., and Nomura S. Vascular endothelial growth factor as a non-invasive marker of pulmonary vascular remodeling in patients with bronchitis-type of COPD. Respir Res 8 (2007) 22
20. Kasahara Y., Tuder R.M., Taraseviciene-Stewart L., Le Cras T.D., Abman S., Hirth P.K., et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 106 (2000) 1311-1319
21. Petrache I., Natarajan V., Zhen L., Medler T.R., Richter A.T., Cho C., et al. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 11 (2005) 491-498
22. Culpitt S.V., Rogers D.F., Traves S.L., Barnes P.J., and Donnelly L.E. Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med 99 (2005) 703-710
23. Daguès N., Pawlowski V., Sobry C., Hanton G., Borde F., Soler S., et al. Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: TIMP-1, a potential predictive biomarker. Toxicol Sci 100 1 (2007) 5-6
24. Mercer P.F., Shute J.K., Bhowmik A., Donaldson G.C., Wedzicha J.A., and Warner J.A. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res 6 (2005) 151
25. Wang Z., Zheng T., Zhu Z., Homer R.J., Riese R.J., Chapman Jr. H.A., et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med 192 (2000) 1587-1600
26. Ruppel G.L. Spirometric determination of chronic obstructive pulmonary disease. J Organ Dysfunction 3 4 (2007) 221-223
27. Ito K. Does lung aging have an impact on chronic obstructive pulmonary disease?. J Organ Dysfunction 3 4 (2007) 204-220
28. Doherty D.E. Assessing the prognosis of patients with chronic obstructive pulmonary disease. J Organ Dysfunction 3 4 (2007) 250-254
29. Barnes P.J. Future therapies for chronic obstructive pulmonary disease. J Organ Dysfunction 4 2 (2008) 66-70
30. Cabrero A., Laguna J.C., and Vázquez M. Peroxisome proliferator-activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy 1 (2002) 243-248
31. Birrell M.A., Patel H.J., McCluskie K., Wong S., Leonard T., Yacoub M.H., et al. PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur Respir J 24 (2004) 18-23
32. Liu D., Zeng B.X., Zhang S.H., and Yao S.L. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm Res 54 (2005) 464-470
33. Henderson B.C., Sen U., Reynolds C., Moshal K.S., Ovechkin A., Tyagi N., et al. Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone. Int J Biol Sci 3 (2007) 385-392
34. Okada M., Yamashita C., Okada M., and Okada K. Contribution of endothelin-1 to warm ischemia/reperfusion injury of the rat lung. Am J Respir Crit Care Med 152 6 Pt 1 (1995) 2105-2110